Literature DB >> 29218740

Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration.

Dionna J Green1, Xiaomei I Liu1, Tianyi Hua2, Janelle M Burnham1, Robert Schuck1, Michael Pacanowski1, Lynne Yao3, Susan K McCune4, Gilbert J Burckart1, Issam Zineh1.   

Abstract

Clinical trial enrichment involves prospectively incorporating trial design elements that increase the probability of detecting a treatment effect. The use of enrichment strategies in pediatric drug development has not been systematically assessed. We analyzed the use of enrichment strategies in pediatric trials submitted to the US Food and Drug Administration from 2012-2016. In all, 112 efficacy studies associated with 76 drug development programs were assessed and their overall success rates were 78% and 75%, respectively. Eighty-eight trials (76.8%) employed at least one enrichment strategy; of these, 66.3% employed multiple enrichment strategies. The highest trial success rates were achieved when all three enrichment strategies (practical, predictive, and prognostic) were used together within a single trial (87.5%), while the lowest success rate was observed when no enrichment strategy was used (65.4%). The use of enrichment strategies in pediatric trials was found to be associated with trial and program success in our analysis.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2018        PMID: 29218740      PMCID: PMC6441612          DOI: 10.1002/cpt.971

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Enrichment of clinical study populations.

Authors:  R Temple
Journal:  Clin Pharmacol Ther       Date:  2010-10-13       Impact factor: 6.875

2.  Failed Pediatric Drug Development Trials.

Authors:  J D Momper; Y Mulugeta; G J Burckart
Journal:  Clin Pharmacol Ther       Date:  2015-06-26       Impact factor: 6.875

3.  Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy.

Authors:  Gerold T Wharton; M Dianne Murphy; Debbie Avant; John V Goldsmith; Grace Chai; William J Rodriguez; Eric L Eisenstein
Journal:  Pediatrics       Date:  2014-07-14       Impact factor: 7.124

4.  Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study design.

Authors:  Jeremiah D Momper; Alyson Karesh; Dionna J Green; Mark Hirsch; Mona Khurana; Jinoo Lee; Myong-Jin Kim; Yeruk Mulugeta; Hari C Sachs; Lynne Yao; Gilbert J Burckart
Journal:  J Clin Pharmacol       Date:  2014-06-24       Impact factor: 3.126

Review 5.  Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents.

Authors:  Haihao Sun; Eric Bastings; Jean Temeck; P Brian Smith; Angela Men; Veneeta Tandon; Dianne Murphy; William Rodriguez
Journal:  JAMA Pediatr       Date:  2013-03-01       Impact factor: 16.193

  5 in total
  1 in total

Review 1.  The "rights" of precision drug development for Alzheimer's disease.

Authors:  Jeffrey Cummings; Howard H Feldman; Philip Scheltens
Journal:  Alzheimers Res Ther       Date:  2019-08-31       Impact factor: 6.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.